Cargando…

Safety of Intravitreal Zoledronic Acid, an Anti-angiogenic Bisphosphonate, in a Rat Model

PURPOSE: To determine the safety of intravitreal zoledronic acid (ZA) in the rat eye. METHODS: Twenty eyes of 20 pigmented rats were randomized into five groups to receive an intravitreal injection of 8, 4, 2 and 1 micrograms (mcg) of ZA, or balanced salt solution (BSS). One week and one month after...

Descripción completa

Detalles Bibliográficos
Autores principales: Nourinia, Ramin, Ahmadieh, Hamid, Rezaei-Kanavi, Mozhgan, Shoeibi, Nasser, Kamrava, Kiana, Karimi, Saeed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ophthalmic Research Center 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4074473/
https://www.ncbi.nlm.nih.gov/pubmed/24982731
_version_ 1782323221373124608
author Nourinia, Ramin
Ahmadieh, Hamid
Rezaei-Kanavi, Mozhgan
Shoeibi, Nasser
Kamrava, Kiana
Karimi, Saeed
author_facet Nourinia, Ramin
Ahmadieh, Hamid
Rezaei-Kanavi, Mozhgan
Shoeibi, Nasser
Kamrava, Kiana
Karimi, Saeed
author_sort Nourinia, Ramin
collection PubMed
description PURPOSE: To determine the safety of intravitreal zoledronic acid (ZA) in the rat eye. METHODS: Twenty eyes of 20 pigmented rats were randomized into five groups to receive an intravitreal injection of 8, 4, 2 and 1 micrograms (mcg) of ZA, or balanced salt solution (BSS). One week and one month after the injections, all eyes were evaluated for intraocular inflammation. Electroretinography (ERG) was performed before, and one week and one month after the injections. All eyes were enucleated one month after the injection for histologic examination. RESULTS: No significant inflammatory response was observed in any eye. No significant decrease in ERG amplitude (a & b waves) was observed one week and one month after intravitreal ZA injection, as compared to baseline, BSS-treated eyes or non-injected fellow eyes. Histologic examination of the retinal pigment epithelium and neurosensory retina were unremarkable in all groups. Additionally, no significant increase in immune reactivity for glial fibrillary acidic protein was noted in any eye. CONCLUSION: Based on clinical, histopathologic and ERG findings in this experimental study, up to 8 mcg of intravitreal zoledronic acid seems to be safe in the rat eye.
format Online
Article
Text
id pubmed-4074473
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Ophthalmic Research Center
record_format MEDLINE/PubMed
spelling pubmed-40744732014-06-30 Safety of Intravitreal Zoledronic Acid, an Anti-angiogenic Bisphosphonate, in a Rat Model Nourinia, Ramin Ahmadieh, Hamid Rezaei-Kanavi, Mozhgan Shoeibi, Nasser Kamrava, Kiana Karimi, Saeed J Ophthalmic Vis Res Original Article PURPOSE: To determine the safety of intravitreal zoledronic acid (ZA) in the rat eye. METHODS: Twenty eyes of 20 pigmented rats were randomized into five groups to receive an intravitreal injection of 8, 4, 2 and 1 micrograms (mcg) of ZA, or balanced salt solution (BSS). One week and one month after the injections, all eyes were evaluated for intraocular inflammation. Electroretinography (ERG) was performed before, and one week and one month after the injections. All eyes were enucleated one month after the injection for histologic examination. RESULTS: No significant inflammatory response was observed in any eye. No significant decrease in ERG amplitude (a & b waves) was observed one week and one month after intravitreal ZA injection, as compared to baseline, BSS-treated eyes or non-injected fellow eyes. Histologic examination of the retinal pigment epithelium and neurosensory retina were unremarkable in all groups. Additionally, no significant increase in immune reactivity for glial fibrillary acidic protein was noted in any eye. CONCLUSION: Based on clinical, histopathologic and ERG findings in this experimental study, up to 8 mcg of intravitreal zoledronic acid seems to be safe in the rat eye. Ophthalmic Research Center 2014-01 /pmc/articles/PMC4074473/ /pubmed/24982731 Text en © 2014 Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences http://creativecommons.org/licenses/by-nc/3.0/ This work is licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.
spellingShingle Original Article
Nourinia, Ramin
Ahmadieh, Hamid
Rezaei-Kanavi, Mozhgan
Shoeibi, Nasser
Kamrava, Kiana
Karimi, Saeed
Safety of Intravitreal Zoledronic Acid, an Anti-angiogenic Bisphosphonate, in a Rat Model
title Safety of Intravitreal Zoledronic Acid, an Anti-angiogenic Bisphosphonate, in a Rat Model
title_full Safety of Intravitreal Zoledronic Acid, an Anti-angiogenic Bisphosphonate, in a Rat Model
title_fullStr Safety of Intravitreal Zoledronic Acid, an Anti-angiogenic Bisphosphonate, in a Rat Model
title_full_unstemmed Safety of Intravitreal Zoledronic Acid, an Anti-angiogenic Bisphosphonate, in a Rat Model
title_short Safety of Intravitreal Zoledronic Acid, an Anti-angiogenic Bisphosphonate, in a Rat Model
title_sort safety of intravitreal zoledronic acid, an anti-angiogenic bisphosphonate, in a rat model
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4074473/
https://www.ncbi.nlm.nih.gov/pubmed/24982731
work_keys_str_mv AT nouriniaramin safetyofintravitrealzoledronicacidanantiangiogenicbisphosphonateinaratmodel
AT ahmadiehhamid safetyofintravitrealzoledronicacidanantiangiogenicbisphosphonateinaratmodel
AT rezaeikanavimozhgan safetyofintravitrealzoledronicacidanantiangiogenicbisphosphonateinaratmodel
AT shoeibinasser safetyofintravitrealzoledronicacidanantiangiogenicbisphosphonateinaratmodel
AT kamravakiana safetyofintravitrealzoledronicacidanantiangiogenicbisphosphonateinaratmodel
AT karimisaeed safetyofintravitrealzoledronicacidanantiangiogenicbisphosphonateinaratmodel